This is a repository copy of *Genetics and sychosis*.

White Rose Research Online URL for this paper:
http://eprints.whiterose.ac.uk/87018/

Version: Accepted Version

**Article:**

https://doi.org/10.1192/apt.bp.113.011189

---

**Reuse**
Unless indicated otherwise, fulltext items are protected by copyright with all rights reserved. The copyright exception in section 29 of the Copyright, Designs and Patents Act 1988 allows the making of a single copy solely for the purpose of non-commercial research or private study within the limits of fair dealing. The publisher or other rights-holder may allow further reproduction and re-use of this version - refer to the White Rose Research Online record for this item. Where records identify the publisher as the copyright holder, users can verify any specific terms of use on the publisher's website.

**Takedown**
If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request.
SUMMARY

Genetic research into psychotic disorders is advancing rapidly. Based on general evidence for genetic influences from family, twin and adoption studies, molecular genetic studies, particularly genome-wide association studies (GWAS), are identifying a range of common genetic risk factors that each have a small effect on risk, while certain chromosomal copy number variants (CNVs) are rarer but have a larger effect on risk. There is also evidence for partial overlap of genetic influences among psychotic disorders and with non-psychotic disorders. This article summarizes the main themes, current findings and potential future directions.

DECLARATION OF INTEREST

None.
Key issues for research into genetic influences on psychotic disorders include: defining the phenotype; investigating general evidence for genetic influences with family, twin and adoption studies; and determining the chromosomal location of DNA risk variants using linkage and association studies. This leads to investigations of the functional/physiological effects of risk variants, with the potential for, e.g. identifying new treatment targets.

**Phenotypes**

The commonest phenotype is a main-lifetime diagnosis of a particular psychotic disorder or group of disorders. Complimentary approaches include the use of endophenotypes involving, e.g. brain imaging or cognitive measures (Gottesman 2003), and quantitative clinical phenotypes, e.g. symptom scores.

**Family, twin and adoption studies**

There is strong evidence for familial influences on psychotic disorders. Family studies of schizophrenia show that compared with the general population lifetime risk of 0.8-1%, the risk to siblings is around 8-10%, with greater risks as more relatives are affected (Gottesman 1991; Lichtenstein 2009).

Twin studies are consistent with at least part of this familial effect being due to genetic influences, in that monozygotic (MZ) twin pairs have considerably higher concordance (~45%) than dizygotic (DZ) twin pairs (~5-10%) (Cardno 2000). Adoption studies are also consistent with genetic influences, in that biological relatives show an elevated risk of schizophrenia despite being separated by adoption and so having little sharing of environmental influences (Lichtenstein 2009).

On the other hand, the fact that over 50% of monozygotic co-twins are unaffected, despite being virtually identical genetically, indicates that non-inherited risk factors are also important.
The degree of genetic influences is often investigated by calculating the heritability, based on concordances in MZ and DZ twins (or other relatives) and the lifetime-risk of the disorder. Heritability estimates for schizophrenia are substantial (60-80%) (Cardno 2000; Sullivan 2003; Lichtenstein 2009).

It is likely that the aetiology is usually multifactorial, i.e. many genetic and environmental factors act together to influence risk, and a single risk factor is unlikely to cause the disorder on its own.

Similar patterns of risks in relatives and heritability are also seen for schizoaffective disorder and bipolar disorder. Additionally, there is evidence that genetic influences on schizophrenia and mania/bipolar disorder partly overlap (Cardno 2002; Lichtenstein 2009), and are also shared with schizoaffective disorder and other psychotic and non-psychotic disorders.

**Molecular genetics**

Based on this general evidence, molecular genetic investigations are conducted to localise DNA risk variants on particular chromosomes. These investigations use genetic markers, DNA sequences that vary between individuals and whose chromosomal location is known, which act as signposts to causal DNA variants close-by.

Linkage studies are based on families with more than one affected member, and investigate whether genetic markers and the disorder are inherited together more frequently than expected. Association studies are population-based and are commonly case-control studies employing single nucleotide polymorphisms (SNPs) as genetic markers, which involves investigating whether, at a particular point in the DNA sequence, a particular DNA base occurs more commonly in cases than controls.
Initial linkage studies and small-scale association studies gave inconsistent results, so current research focuses on large-scale genome-wide association studies (GWAS) involving tens of thousands of participants and a million or more measured and estimated SNP genetic markers (Craddock 2013).

The first substantive GWAS finding for schizophrenia was for a marker in the gene ZNF804A on chromosome 2 (O’Donovan 2008), and further associations have followed as sample sizes have increased. Currently, the most consistent GWAS association is in the major histocompatibility complex (MHC) on chromosome 6 (Ripke 2011). This region contains many immune system genes, but the exact location and function of the schizophrenia risk variant(s) are not yet known.

There are also GWAS associations for bipolar disorder, including in the ion channel gene CACNA1C (Sklar 2011), and evidence for partial overlap of genetic influences on schizophrenia, bipolar disorder, and other psychiatric disorders (Sullivan 2012; Cross-Disorder Group of the PGC 2013). As GWAS sample sizes increase, many more associations are expected.

GWAS focus on detecting common genetic variants that each have a very small effect on risk. In contrast, larger-scale chromosomal variants, particularly deletions or duplications known as copy number variants (CNVs), are rarer but have a larger effect on risk. CNVs are associated with schizophrenia (Sullivan 2012) and, e.g. learning disability and autism spectrum disorders, but are less associated with bipolar disorder.

There are probably also other types of risk variant (Sullivan 2012), and large-scale DNA sequencing studies are underway to identify these.
Once risk variants are identified, their physiological consequences are investigated with the aim of improving our understanding of the pathophysiology and identifying new targets for treatment. There is also potential to gain insights into gene-environment interplay, including through epigenetic mechanisms, and to inform the classification of psychotic disorders. Molecular genetic risk factors do not currently have a practical role in predicting risk of developing psychotic disorders, but this may change in future, e.g. through combined analyses of multiple genetic and environmental factors.

References


Craddock N (2013) Genome-wide association studies: what a psychiatrist needs to know. Advances in Psychiatric Treatment 19: 82-8


